You are here
Accessing e-cigarettes containing liquid nicotine
Electronic cigarettes containing liquid nicotine, also known as e-cigarettes, electronic nicotine delivery systems (ENDS) or e-cigs, are devices for making vapour for inhalation (vaping). E-cigarettes are considered by some health professionals as an option to help people quit smoking, although this view is strongly contested as the published evidence is mixed.
There are restrictions on the importation of these products, for more information see:
- Australian Government proposes strengthening its stance against e-cigarettes containing vaporiser nicotine
- Prohibition on importing e-cigarettes containing vaporiser nicotine
Information for consumers
To date, no e-cigarette products have been approved as smoking cessation aids in Australia. These products are considered to be 'unapproved' therapeutic goods and the TGA has not evaluated them for quality, safety and effectiveness.
E-cigarettes containing nicotine and nicotine for use in e-cigarettes to help a person to quit smoking can be prescribed by an Australian registered doctor and supplied with approval from the TGA. If you think these products may help you to quit smoking, you should speak to your doctor. If they believe it is the most appropriate treatment for your situation, they will be able to apply to the TGA for the necessary approval and help to arrange supply.
There are registered (TGA-approved) smoking cessation medicines in Australia. These include nicotine replacement therapies (including sprays, patches, lozenges and chews) available without prescription either over-the-counter in pharmacies or in some cases from other retailers. There are also prescription medicines that can help you quit, as well as a range of non-medicine approaches to smoking cessation.
For help with quitting, talk to your health professional or phone the Quitline on 13 7848. Alternatively, visit the Quit Now website.
Information for health professionals
E-cigarettes containing nicotine and nicotine for use in vaporisers can be supplied under the Special Access Scheme (SAS) or the Authorised Prescriber Scheme, if you believe it is the most appropriate therapy for your patient.
Therapeutic goods must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be lawfully imported into, exported from or supplied in Australia unless otherwise the subject of an exemption, approval or authority under the Therapeutic Goods Act 1989.
To date, no e-cigarettes (including nicotine containing e- cigarettes) have been approved in Australia as a therapeutic good for smoking cessation. However, there may be circumstances where products that are not included in the ARTG (also referred to as 'unapproved medicines') may be appropriate. In these situations, there are a number of pathways through which Australian registered prescribers may access unapproved medicines on behalf of their patient(s):
Special Access Scheme
The SAS provides for the import and supply of an unapproved therapeutic good to a single patient on a case-by-case basis. SAS Category B may be used by prescribers to access liquid nicotine and nicotine-containing liquids for the purposes of smoking cessation.
Consistent with the requirements of SAS and in accordance with good medical practice, prescribers should consider appropriate approved treatment options that are included on the ARTG before considering accessing an unapproved e-cigarette product for a patient.
In addition, the prescriber, and the patient through informed consent take responsibility for any adverse consequences of treatment with the unapproved product.
Depending on the product, import restrictions and state and territory requirements may apply. SAS approval does not override these requirements.
See the Special Access Scheme webpage and guidance material for further information.
The SAS Online System is the preferred method of submission to reduce processing times for applicants:
SAS B forms are also available at:
Authorised Prescriber scheme
A doctor may be granted authority to become an 'Authorised Prescriber' of a specified unapproved therapeutic good (or class of unapproved therapeutic goods) to specific patients (or classes of recipients) with a particular medical condition. Once a doctor becomes an Authorised Prescriber, they do not need to notify the TGA each time they prescribe the unapproved medicine during the period of approval. However, they must report to the TGA the number of patients treated every six months. For information regarding the Authorised Prescriber scheme, please refer to the Authorised Prescriber Scheme Guidance for Medical Practitioners, Human Research Ethics Committees, Specialist Colleges and Sponsors.
- The Australian Government has released National guiding principles for e-cigarettes (pdf,843kb).
- The Royal Australian College of General Practitioners (RACGP) have recently published the second edition of the RACGP's Supporting smoking cessation: A guide for health professionals
State and territory requirements
Please note that state and territory governments have specific requirements regarding sale and possession of e-cigarette products. These differ between each state and territory. For further information, it is strongly recommended that you contact your local state/ territory health department prior to prescribing or travelling into Australia with e-cigarette products, to determine if there are any other restrictions on the possession and use of electronic cigarettes obtained with a medical prescription.
The TGA has an important role in monitoring the safety of unapproved medicines and we strongly encourage consumers and health professionals to report any suspected adverse events involving e- cigarettes. Reporting adverse events helps us to build a profile of the safety of a medicine. Significant safety concerns are investigated as part of ensuring product safety in the Australian community.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine.